Background. The aims of the study were to identify the significance of interleukin (IL)-6 production and to determine whether IL-6 production influences long-term survival in patients with non-small-cell lung cancer (NSCLC). Method. A series of 90 patients with NSCLC who underwent surgery between 2005 and 2007 was analyzed. Preoperative serum IL-6 was measured, and tumor samples were immunohistochemically stained for IL-6. Results. Serum IL-6 levels were elevated in 43 of 90 cases (47.7%), and 23 (25.5%) of 90 cases stained positively for IL-6 (P = .00265). The prognosis of patients with NSCLC who had positive immunohistochemical staining was significantly worse than that for those who had negative staining, by univariate analysis (P = .0027). Multivariate analysis indicated that tumor size, postoperative stage, and overexpression of IL-6 were independent prognostic factors. Conclusions. The expression of IL-6 in tumor correlated with the concentration of serum IL-6, tumor progression, and overall survival in patients with NSCLC.
IgG4-related disease often forms a mass and the affected lesion is clinically removed because the mass cannot be differentiated from a neoplasm. Affected lesions commonly occur in the pancreas, hepatobiliary tract, kidney, and retroperitoneum. However, the lesion rarely occurs in the thymus. A histological worldwide consensus of IgG4-related disease proposed that pathological diagnosis of IgG4-related disease should meet more than two of three major features: 1) dense lymphoplasmacytic infiltration with greater than 40% IgG4+/IgG+ plasma cells, 2) storiform fibrosis; and 3) obliterative phlebitis. Currently, fibrosis of IgG4-related disease is thought to be induced by profibrotic cytokines such as transforming growth factor beta 1 (TGFB1), interleukin 1 beta (IL1B) and interferon gamma (IFNG), which are secreted by regulatory T cells (Tregs) and CD4-positive cytotoxic T cells. However, it is unclear whether profibrotic cytokines are associated with the fibrosis seen in IgG4-related thymitis. Here we examined whether cytokines in the mass were increased compared with those in the surrounding thymus, and whether Tregs were present in the mass, using reverse transcription absolute quantitative polymerase chain reaction (RT-ab-qPCR) and immunohistochemistry. A 70-year-old Japanese man contracted IgG4-letated thymitis. Histological and immunohistochemical analyses demonstrated his mass had massive fibrosis with a focally storiform pattern and lymphoplasmacytic infiltration with 40% IgG4+/IgG+ plasma cells, but not obliterative phlebitis. The mass was surrounded by atrophic thymus. We diagnosed the mass as IgG4-related thymitis. Immunohistochemically, Tregs were scattered throughout the mass. RT-ab-qPCR showed that messenger RNA expressions of TGFB1, IL1B and IFNG in the mass were 270-, 158- and 5.5- fold higher than in the surrounding thymus. His serum IgG4 level after surgery was within the normal range (83.4 mg/dl soon after surgery, 89.3 mg/dl 2 weeks after surgery). Our results suggested the profibrotic cytokines TGFB1, IL1B and IFNG induce fibrosis and that Tregs might produce some of these cytokines in IgG4-related thymitis as well as in the other affected lesions of IgG4-related disease.
1 December 2010 in Interactive CardioVascular and Thoracic Surgery
We report a case of a 67-year-old woman with stage IIIB locally advanced non-small cell lung cancer who had also suffered from hyperthyroidism with persistent atrial fibrillation (AF). Thiamazole provided euthyroid status, but medication failed to resolve AF. A computed tomography (CT)-scan revealed a 5×5-cm mass in the left hilar region that involved the left atrium (LA) and bifurcation of the pulmonary artery. Left pneumonectomy, LA partial resection and reconstruction of the bifurcation of the pulmonary artery were performed. In addition, a maze procedure was performed using cardiopulmonary bypass and cardiac arrest. We present the first case report of advanced lung cancer surgery with a maze procedure. Follow-up by CT-scan 34 months later did not show any recurrence and attacks of AF (no medication after surgery) were completely resolved after the operation.
Spontaneous pneumothorax in a tuberculosis-induced destroyed lung is uncommon and challenging, particularly when surgery poses prohibitive risk. Practical, non-surgical strategies that reliably control persistent air leak are therefore needed. A 48-year-old woman with prior pulmonary tuberculosis and a destroyed right lung presented with right-sided pneumothorax. On arrival, she maintained adequate oxygenation on room air and did not require supplemental oxygen. Despite appropriate chest drainage, a persistent air leak continued for more than 2 weeks. Chemical pleurodesis was performed via the chest tube using a combined regimen of minocycline 100 mg diluted in 50 mL normal saline plus 50 mL autologous blood (total instilled volume 100 mL). Because leakage persisted, a second pleurodesis with the same regimen was performed 48 hours later. Within 24 hours after the second procedure, the air leak ceased. Follow-up chest radiography confirmed re-expansion, the chest tube was removed on day 21, and the patient was discharged without complications. Outpatient follow-up at approximately 2 weeks, 1 month, and 3 months included chest radiographs at the first two visits; no recurrence was observed, and the patient reported satisfactory daily activity without dyspnea beyond baseline. In high-risk patients with post-tuberculosis destroyed lung and persistent air leak, combined autologous blood and minocycline pleurodesis can provide effective, bedside control and avert surgery. This case details a simple two-step protocol with explicit dosing and timing that may be considered when operative management is unsuitable.
5 November 2025 in Respiratory Medicine Case Reports
Catamenial pneumothorax (CP) is a rare form of spontaneous pneumothorax associated with thoracic endometriosis. We report a case of CP with histologically proven diaphragmatic endometriosis successfully managed by combined surgical resection and hormonal therapy, achieving a four-year recurrence-free outcome.